ReviewMaterials today. Bio2025
Improving tumor treatment: Cell membrane-coated nanoparticles for targeted therapies.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Biomimetic self-assembled copper nanoadjuvant potentiates hepatocellular carcinoma immunotherapy via cuproptosis-driven cGAS-STING activation.Materials today. Bio · 2026Article
- Macrophage Membrane-Engineered Biomimetic Nanoplatform Enables Immune Evasion and Immunomodulation for Enhanced Chemo-Photodynamic Therapy.Biomacromolecules · 2026Article
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- Platelet membrane-coated nanoparticles: Bioengineering principles, quality control, and translational opportunities.APL bioengineering · 2026Review
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- Advances of Cell Membrane-Coated Nanotechnology and Membrane Vesicles in Intestinal Targeted Drug Delivery Systems.Pharmaceutics · 2026Review
- Oxygen-carrying nanovaccine potentiates cancer immunotherapy for heterogeneous solid tumors.Materials today. Bio · 2026Article
- M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer.Journal of materials science. Materials in medicine · 2026Article
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- Physicochemical design of nanobiomaterials in oncology: structure-to-function principles for sequential transport and delivery.Frontiers in oncology · 2026Review
- Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.Breast cancer (Dove Medical Press) · 2026Review
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
- Glioma Cell Membrane-Coated CaCOInternational journal of nanomedicine · 2026Article
- Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges.Frontiers in pharmacology · 2026Review
- The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine.Science advances · 2025Review
- Special issue: Surface and interface engineering in biomedical applications: Harnessing nature's design.Materials today. Bio · 2025Article
- Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier.Journal of nanobiotechnology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cells membrane-coated nanoparticles (CMs-NPs) represent a highly promising platform in cancer treatment. Due to the various types of cell sources employed and the broad designs of NPs, CM-NPs have emerged as versatile and multifunctional platforms with wide applicability in medicine. This literature review showcases the applications of CMs-NPs in cancer therapy, highlighting significant advancements in tumor-targeted delivery, phototherapy, and immunotherapy. Different cell types employed as CMs sources are reviewed, including cancer cells, red blood cells, platelets, white blood cells, stem cells, fibroblasts, and bacterium. Hybrid CMs-coatings and the technology to produce them are also included. Additionally, the state of the art in methodologies is critically examined, noting that while effective methods for coating and isolation of CMs exist, further optimization is still required. The latest reports and research findings in this regard are also presented, emphasizing the continuous need for innovation to overcome substantial challenges related to this promising nanotechnology. The aim of this review is to provide an in-depth overview of the evolving landscape in the development of effective and targeted cancer treatments, underscoring the transformative potential of CMs-NPs in revolutionizing cancer care and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.